Statera BioPharma (STU:7CB) EBITDA Margin %: 0.00% (As of Sep. 2022)


What is Statera BioPharma EBITDA Margin %?

Statera BioPharma STU:7CB 20 EBITDA Margin % is 0.00% as of Sep. 2022. GuruFocus rates STU:7CB with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Statera BioPharma's EBITDA for the three months ended in Sep. 2022 was €-1.37 Mil. Statera BioPharma's Revenue for the three months ended in Sep. 2022 was €0.00 Mil. Therefore, Statera BioPharma's EBITDA margin for the quarter that ended in Sep. 2022 was 0.00%.

Statera BioPharma  (STU:7CB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Statera BioPharma EBITDA Margin % Related Terms

Statera BioPharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma EBITDA Margin % Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
EBITDA Margin %
0.00 0.00 0.00

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:7CB vs NRBO, PALI, BLCM: EBITDA Margin % Comparison

For the Biotechnology subindustry, Statera BioPharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's EBITDA Margin % falls into.


Statera BioPharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Statera BioPharma's EBITDA Margin % for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-25.72/0
= %

Statera BioPharma's EBITDA Margin % for the quarter that ended in Sep. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2022 )/Revenue (Q: Sep. 2022 )
=-1.369/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Statera BioPharma (STU:7CB) has a EBITDA Margin % of 0.00% as of Sep. 2022. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's EBITDA Margin % too high?
Statera BioPharma's current EBITDA Margin % is 0.00%. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's EBITDA Margin % compare to NRBO and PALI?
Statera BioPharma's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STU:7CB) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Statera BioPharma's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Statera BioPharma (STU:7CB), the current EBITDA Margin % is 0.00% as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.